SCHEMBL3988030

SCHEMBL3988030

COc1ccc(S(=O)(=O)Nc2ccc3cc[nH]c3c2C(=O)O)c(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 1/20 0.45
PTPN2 P17706 1/20 0.45
PTPN1 P18031 1/20 0.45
PTPRB P23467 1/20 0.45
PTPRE P23469 1/20 0.45
PTPN6 P29350 1/20 0.45
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
ALPL P05186 1/20 0.43
ALDH1A1 P00352 3/20 0.43
NPSR1 Q6W5P4 1/20 0.43
FABP4 P15090 1/20 0.40
ACLY P53396 3/20 0.40
SLC40A1 Q9NP59 1/20 0.40
GAA P10253 2/20 0.39
CDK5 Q00535 1/20 0.39
CDK5R1 Q15078 1/20 0.39
MAPT P10636 2/20 0.39
HTT P42858 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3982737 0.83 ESR1 (0.53) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL3985610 0.74 PTPRC (0.53) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL3982699 0.73 METAP2 (0.63) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL3985804 0.73 ACLY (0.52) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL3982706 0.72 PTPRC (0.53) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL3984731 0.72 METAP2 (0.55) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL3982247 0.71 PTPRC (0.49) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL3988437 0.70 METAP2 (0.62) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL3984541 0.69 MEN1 (0.59) MEN1KMT2AALPLALDH1A1FABP4
SCHEMBL3982513 0.69 METAP2 (0.49) PTPRCPTPN2PTPN1PTPRBPTPRE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7491718-B2 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES (US) 2009-02-17 US disclosed
EP-1549613-A1 SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY Abbott Laboratories (US) 2005-07-06 EP disclosed
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity ABBVIE INC. 2004-08-26 US disclosed
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-08-12 US disclosed
WO-2004033419-A1 SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY ABBOTT LABORATORIES (US) 2004-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP PTPRC 2454/4885PTPN2 964/4885PTPN1 2479/4885
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP PTPRC 2454/4885PTPN2 964/4885PTPN1 2479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.